InnoCare Pharma, a Chinese cancer drug developer backed by the Asian private equity (PE) major Hillhouse Capital Group, has moved closer to a planned secondary listing on Shanghai’s Nasdaq-style STAR Market that could raise about 4 billion yuan ($620.4 million).
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com